Pediatric pharmacogenomics from whole-exome sequencing: developmentally appropriate interpretation in 1,159 Russian children and newborns

Every child is unique, but in the world of medicine, a child is also fundamentally different from an adult. This is not just a matter of size; it is a matter of biology in motion. Inside a growing body, the chemical machinery that processes medicines is constantly changing. Enzymes, which act like tiny workers breaking down drugs, and transport proteins, which move medicines through the body, do not function the same way in a newborn as they do in a teenager or a grown person. Their activity levels rise and fall as the child develops. This creates a tricky problem for doctors trying to use pharmacogenomics, a field that tailors treatment based on a person's genetic code. While scientists have learned how to read genes to predict how an adult will react to a drug, those same rules often fail when applied to children. A genetic variant that signals a need for a lower dose in an adult might mean nothing, or even the opposite, in a baby whose liver enzymes are not yet fully active.

Researchers in Russia set out to solve this disconnect by looking at the genetic data of over 1,100 Russian children and newborns. They wanted to see if the standard genetic reports used for adults could safely guide treatment for kids, or if the rapid changes of childhood made those reports misleading. By analyzing the DNA of 524 pediatric patients and 635 newborns, the team discovered that simply applying adult rules to children is a dangerous gamble. They found that when they filtered their genetic data to include only the most reliable, evidence-backed information relevant to children, the number of useful findings dropped dramatically. Most of the genetic markers that looked important for adults were either irrelevant or too uncertain to act upon in a child.

The study revealed a startling gap between what the genes say and what the body is actually doing. When the researchers compared the genetic recommendations for newborns against the known developmental status of their drug-metabolizing enzymes, the two matched in less than half of the cases. For instance, a genetic test might suggest a child needs a lower dose of a blood thinner because of a specific gene variant. However, because the newborn's liver enzymes are naturally immature and working at a fraction of adult capacity, the child might actually need a different dose entirely, or the genetic clue might be completely overpowered by their age. In some cases, the genetic advice was directly at odds with the biological reality of a newborn, suggesting that following the genetic report alone could lead to the wrong treatment.

To understand how this plays out in real life, the team looked back at the medical records of 100 children from their group. They found that nearly one in five of these children had experienced an adverse reaction to a medication, ranging from allergic rashes to severe, life-threatening complications. Yet, when they tried to explain these reactions using the high-quality genetic data available, they could only account for two cases. This suggests that while genetics plays a role, the current tools are missing the vast majority of the story. The reactions that occurred were often due to factors that genetic tests simply cannot predict yet, or they were driven by the complex interplay of a child's developing body and the drugs they were taking.

The researchers also calculated which genetic risks would cause the most trouble for the largest number of people if left unaddressed. They weighed how common a specific gene variant was against the cost and severity of the bad reaction it could cause. This analysis pointed to two major priorities: a genetic variant linked to severe skin reactions from the epilepsy drug carbamazepine, and another linked to dangerous drops in white blood cells from the chemotherapy drug irinotecan. These specific combinations represent the areas where testing children could save the most lives and prevent the most suffering. However, the team emphasized that even for these high-priority cases, the advice must be adjusted for age. A child's reaction to a drug is not just about their DNA; it is about their DNA at a specific moment in their growth.

The paper concludes that the current way of writing genetic reports is broken for children because it ignores the timeline of human development. A report that tells a doctor to change a dose based on a gene, without mentioning the patient's age or how their liver is maturing, is incomplete and potentially harmful. The authors propose a new model where every genetic finding is paired with a clear statement about whether it applies to a newborn, a toddler, or an older child. They argue that doctors, geneticists, and pharmacologists must work together to interpret these results, ensuring that the advice given fits the child's current stage of life. Until this age-aware approach becomes standard, the promise of personalized medicine for children will remain out of reach, leaving doctors to guess rather than know how to treat their youngest patients safely.